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Abstract Thermal therapy for heart failure is recognized to improve clinical symp-
toms. We describe our experience with appendicular thermal therapy applied to aCardiomyopathies; patient ﬁtted with an extracorporeal left ventricular assist device (LVAD) who was
transplant. A 21-year-old male with end-stage heart failureDilated; wait-listed for a heartHeart failure;
Treatment;
Thermal therapy;
Transplantation
due to dilated cardiomyopathy was ﬁtted with a LVAD. His general condition stabi-
lized after LVAD placement and the status of his heart failure has remained at NYHA
class II for the past 13 months. However, his cardiac function did not sufﬁciently
recover to discontinue LVAD support. We conducted appendicular thermal therapy
using a steam foot bath and heated gloves for 2 weeks. Immediately after thermal
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therapy, his average sublingual temperature increased from 36.3 to 37.0 ◦C and the
grade of mitral regurgitation, as well as LV ejection fraction and endothelial func-
tion improved. Furthermore, levels of oxidative and anti-oxidative stress markers
decreased and increased, respectively, after 2 weeks of therapy. No complications
developed. We conclude that appendicular thermal therapy was safe in this patient
waiting for a heart transplant and who had an extracorporeal LVAD, and that the
procedure might be beneﬁcial for others with end-stage heart failure.
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Introduction
Previous studies have demonstrated the safety and
efﬁcacy of systemic thermal therapy for patients
with chronic heart failure (CHF) [1—5]. A large num-
ber of patients in Japan have been implanted with a
left ventricular assist device (LVAD) because of pro-
longed waits for heart transplants [6]. Although we
wished to apply sauna thermal therapy to patients
with LVAD, we do not have an appropriate sauna
facility. Thus, we attempted to apply appendicu-
lar thermal therapy to a patient with LVAD awaiting
a heart transplant. We describe for the ﬁrst time
the safety and effectiveness of this strategy for a
patient with end-stage heart failure.
Case reportA 21-year-old man with dilated cardiomyopathy
refractory to maximal medical therapy was admit-
ted to our hospital in April 2006. Regardless of
Fig. 1 Setup of appendicular thermal therapy for patient ﬁ
Patient is fully reclined and relaxed.
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ntensive care with intravenous inotropic agents,
is heart failure rapidly progressed to cardiogenic
hock. He was ﬁtted with an extracorporeal LVAD
VCT-50; Toyobo Ltd., Osaka, Japan) 1 week after
dmission. His general condition stabilized there-
fter and the status of heart failure at that time was
YHA class II. Although this status remained stable
or 6 months, his cardiac function did not sufﬁ-
iently recover to discontinue LVAD support. He has
emained stable in NYHA class II for 13 months with
he LVAD. The patient provided written informed
onsent to enter into a clinical trial of appendicu-
ar thermal therapy for patients with LVAD awaiting
or a heart transplant. The Ethics Committee at
he National Cardiovascular Center approved the
rotocol, and the study was conducted in accor-
ance with the Declaration of Helsinki. The study
onsisted of clinical examinations before and aftertted with extracorporeal left ventricular assist device.
aily thermal therapy for 2 weeks using a steam
ath at 42 ◦C for the lower legs and feet, and
eated gloves at the same temperature for both
rms (Fig. 1). After 15min of therapy at 42 ◦C,
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he patient remained seated in the steam bath
ith the lower legs and feet wrapped with a blan-
et for 30min. The procedure was accompanied
y electrocardiographic monitoring. The patient
emained on the following medications throughout
he study period: beta-blocker (carvedilol 22.5mg),
ngiotensin-converting enzyme inhibitor (enalapril
3
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Table 1 Clinical parameters before and after thermal ther
ADL according to SAS (Mets)
Cardiothoracic ratio (%)
Blood pressure (mmHg)
Heart rate (bpm)
Ventricular premature beats (beats/day)
Body temperature (◦C)
Deep body temperature just before heating (◦C)
Deep body temperature just after heating (◦C)
Body weight (kg)
Urine volume (mL)
Complete blood count
White blood cells (/L)
Red blood cells (104/L)
Hemoglobin (g/dL)
Hematocrit (%)
Platelets (104/mL)
Blood chemistry
Total bilirubin (mg/dL)
Aspartate aminotransferase (IU/L)
Alanine aminotransferase (IU/L)
Lactate dehydrogenase (IU/L)
Blood urea nitrogen (mg/dL)
Cr (mg/dL)
Urinary albumin (mg/dL)
Na (mEq/L)
K (mEq/L)
Cl (mEq/L)
C-reactive protein (mg/dL)
Brain natriuretic peptide (pg/mL)
N-terminal pro brain natriuretic peptide (pg/mL)
Norepinephrine (pg/mL)
Diacron reactive oxygen metabolites (Carr U)
OXY absorbent test (mol HClO/mL)
Nitrate + nitrite (M)
Echocardiographic measurements
Left atrial diameter (mm)
Left ventricular diastolic dimension (mm)
Left ventricular systolic dimension (mm)
Fractional shortening (%)
Ejection fraction (%)
Mitral regurgitation (grade)
Endothelial function
RH-PAT (absolute number)
Exercise capacity
300-m walk test (min, s)
ADL, activities of daily living; SAS, speciﬁc activity scale; RH-PAT, R303
.5mg), diuretic (furosemide 20mg), aldosterone
ntagonist (spironolactone 50mg), antiarrhyth-
ic (amiodarone 100mg), anticoagulant (warfarin
.5mg), and antiplatelet drugs (aspirin 100mg).
The patient’s sublingual temperature imme-
iately after 15min of therapy increased from
6.3± 0.31 to 37.0± 0.37 ◦C (P < 0.0001; paired
apy
Baseline 2 Weeks
2 2.3
60.3 58.6
92/59 91/60
74, sinus 67, sinus
15 12
36.7 36.4
36.5 36.5
37.0 37.4
65.7 65.4
1638 1471
9100 7400
459 455
12.3 12
36.6 36
31.1 29.7
0.7 0.7
31 29
17 16
320 316
11 13
0.73 0.81
6.4 6.5
133 135
4 4.2
101 104
0.45 0.38
270 267
857 769
950 893
496 442
343 386
35.0 72.2
46 42
75 76
69 66
8 13
17 27
3 2
1.14 2.28
5′35′′ 4′50′′
eactive hyperemia peripheral arterial tonometry.
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t-test). His blood pressure and heart rate did
not signiﬁcantly differ before and after the ther-
mal therapy (Table 1). The cardiothoracic ratio
decreased from 60.3 to 58.6% (Fig. 2A). Echocar-
diography revealed that left atrial diameter and the
grade of mitral regurgitation decreased (Fig. 2B and
C), and that LV ejection fraction increased after the
therapy (Table 1).
Whereas the level of plasma BNP changed
only slightly after therapy, those of plasma NT-
proBNP and norepinephrine decreased. Diacron
reactive oxygen metabolites (dROM) in serum,
which comprise a marker of oxidative stress [7],
decreased and the OXY absorbent test, a marker
of anti-oxidative potency [8], increased after
r
f
o
w
Fig. 2 Chest X-ray (A), M-mode echocardiogram of left atrial
tation (C) before and 2 weeks after appendicular thermal theH. Higashi et al.
he therapy (Table 1). Serum concentrations of
itrite and nitrate, which are stable derivatives
f nitric oxide, increased after therapy. We also
stimated endothelial function with reactive hyper-
mia peripheral arterial tonometry (RH-PAT) using a
ngertip arterial tonometry device (Endo-PAT; Ita-
ar, Caesarea, Israel) [9]. Brieﬂy, the hyperemic
esponse after 5-min forearm cuff inﬂation was
ssessed as the log of the ratio of the post-deﬂation
o baseline pulse amplitude in the hyperemic ﬁn-
er normalized to the contralateral ﬁnger (log PAT
atio). The log PAT ratio, a measure of endothelial
unction, doubled after therapy (Table 1). More-
ver, the patient required less time for a 300-m
alk after therapy (Table 1).
diameter (B), and 2D echocardiogram of mitral regurgi-
rapy.
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et al. Repeated sauna therapy increases arterial endothelial
nitric oxide synthase expression and nitric oxide productionppendicular thermal therapy for a patient with LV
iscussion
his is the ﬁrst report of appendicular thermal
herapy being applied to a patient implanted with
n LVAD and awaiting a heart transplant. Whole
ody sauna therapy for CHF is widely recognized to
nclude improved clinical symptoms, cardiac func-
ion, quality of life, and ventricular arrhythmia, and
ecreased levels of abnormally activated neurohu-
oral factors [1—5]. However, whole body sauna
herapy is impractical for patients with CHF in
eneral hospitals that lack specialized sauna facili-
ies, whereas appendicular thermal therapy using a
team bath and heated gloves can be applied rou-
inely within patients’ rooms.
Increases in deep body temperature of
.0—1.2 ◦C during sauna therapy dilate systemic
rteries and veins, and reduce systemic preload
nd afterload, resulting in increased cardiac output
1—5]. The sublingual temperature of our patient
fter the therapy increased by about 0.7 ◦C. Never-
heless, the beneﬁts seemed to be similar to those
f sauna therapy. Ikeda et al. found that repeated
auna therapy increases endothelial nitric oxide
ynthase expression and nitric oxide production,
nd improves cardiac function in animal models
f heart failure [10,11]. Serum nitrite and nitrate
evels doubled in our patient compared with the
aseline values, as did the index of endothelial
unction determined by RH-PAT.
Patients implanted with an LVAD for long periods
ften develop serious hemorrhage in the cere-
rum or elsewhere and drive-line infection. We
ere concerned that the therapy would aggravate
emorrhage or infection of patients through its
asodilatory effects. However, we found that oozing
f blood at the insertion site of the LVAD drive-line
ended to resolve during therapy.
Sauna thermal therapy attenuates psychological
tress [4]. Because of a donor shortage in Japan,
atients must remain attached to an LVAD and
tay for over 2 years in hospital while waiting for
heart transplant [12]. The decrease in plasma
orepinephrine indicated that appendicular ther-
al therapy also might attenuate psychological, as
ell as physical stress.onclusion
ppendicular thermal therapy was safe for this
atient with an extracorporeal LVAD waiting for a
[
Available online at www.s305
eart transplant and the procedure might bene-
t other patients, including those with end-stage
eart failure.
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